Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Shivaani Kummar,
Ulrik N Lassen
Department of Clinical Medicine
35
Citations (Scopus)
30
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'TRK Inhibition: A New Tumor-Agnostic Treatment Strategy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
NTRK Fusion
100%
Tumor-agnostic
100%
Larotrectinib
50%
TRK Inhibitors
50%
NTRK3
25%
Entrectinib
25%
Clinical Trial Results
25%
NTRK2
25%
Actionable Genomic Alteration
25%
Biochemistry, Genetics and Molecular Biology
Gene Fusion
100%
Tyrosine Kinase
25%
Receptor Tyrosine Kinase
25%
Chromosomal Rearrangement
25%
Chimeric Protein
25%
Phase II Trials
25%
Genomics
25%
Phase I Trials
25%
Anticancer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Solid Malignant Neoplasm
16%
Phase I Trials
16%
Chimeric Protein
16%
Drug Development
16%
Phase II Trials
16%
Protein Tyrosine Kinase
16%
Clinical Trial Results
16%
Medicine and Dentistry
Larotrectinib
33%
Entrectinib
16%
Clinical Trial Results
16%